Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02909101 · ClinicalTrials.gov registry record · NA

Project IMPACT: Improving Memory Performance by Applying Cognitive Training

A NA study, sponsored by Duke University.

Completed
Registry status
NA
Development phase
58
Enrollment target

NCT02909101: Completed NA study, sponsored by Duke University.

NCT02909101 is a NA study that has completed, run by Duke University. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02909101, a NA study, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target

Study Summary

The purpose of this study is to examine the effects of a cognitive training program in persons with Human Immunodeficiency Virus (HIV) infection who have used cocaine. This study tests the feasibility and preliminary efficacy of a computerized cognitive training program to improve working memory and decrease impulsivity (delay discounting) among HIV-infected individuals.

Primary Outcome

Measured by domain deficit score, which is a continuous measure of overall impairment on the domain. 0 means no impairment and 5 means highest possible impairment.

Interventions

  • DEVICE Active Cognitive Training (ACT)
  • DEVICE Control Training (CON)

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2017-03-01
Est. Completion 2019-02-23
Phase NA
Duke University

1,725 total trials

What the finished NCT02909101 record still lists

NCT02909101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Active Cognitive Training (ACT) is the first listed.

NCT02909101 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02909101 about?

NCT02909101 is a clinical study titled "Project IMPACT: Improving Memory Performance by Applying Cognitive Training". The purpose of this study is to examine the effects of a cognitive training program in persons with Human Immunodeficiency Virus (HIV) infection who have used cocaine. This study tests the feasibility and preliminary efficacy of a computerized cognitive training program to improve working memory and...

What is the current status of trial NCT02909101?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2017-03-01. Estimated completion is 2019-02-23.

What interventions are being tested in trial NCT02909101?

The interventions under investigation include: Active Cognitive Training (ACT) (DEVICE), Control Training (CON) (DEVICE).

Who is sponsoring clinical trial NCT02909101?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02909101's enrollment target sits among peer trials

58 1256th of 2000 higher than 740 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02909101, the US trial registry maintained by the National Library of Medicine. NCT02909101 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.